Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

China Blood Product Industry Report 2018-2022 - Research and Markets

Research and Markets
Posted on: 17 Nov 17

The "Research Report on Blood Product Industry in China, 2018-2022" report has been added to Research and Markets' offering.

China will become one of the major global blood product markets as its economy develops. Chinese government imposes strict regulations on production, sales and import of blood products. In addition, the government implements a lot release system of biological products (including blood products and vaccines), compulsorily inspecting and verifying every batch of such products when leaving factory or being imported. Disqualified or disapproved products should not be on the market or imported.

According to market research by the author, about 30 blood product manufacturers have been authenticated by the Chinese government by the end of 2017. But indeed, only 20 of them operate under normal production. Since 2012, mergers and acquisitions have emerged in China's blood product industry.

Examples include Jiangxi Boya Bio-Pharmaceutical Co., Ltd. purchasing partial stake of Zhejiang Haikang Biological Products Co., Ltd., Beijing Tiantan Biological Products Co., Ltd. acquiring Chengdu Rosen Pharmaceutical Co., Ltd. and Humanwell Healthcare Group Co., Ltd. acquiring Wuhan Rui De Biological Products Co., Ltd.

Key Topics Covered:

Chapter I Basic Concept of Blood Products

Chapter II Overview of Global Blood Product Industry, 2013-2017

Chapter III Operation Status of China Blood Product Industry, 2013-2017

Chapter IV Analysis of Major Blood Product Manufacturers in China, 2016-2018

Chapter V Analysis on Blood Product Industry Chain in China, 2016-2018

Chapter VI Forecast on Development of China Blood Product Industry, 2018-2022

Companies Mentioned

  • Beijing Tiantan Biological Products Co., Ltd.
  • Green Cross (China) Biological Products Co., Ltd.
  • Guangdong Danxia Bio-pharmaceutical Co., Ltd.
  • Guangdong Shuanglin Bio-pharmaceutical Co., Ltd.
  • Guangdong Weilun Bio-pharmaceutical Co., Ltd.
  • Guiyang Qianfeng Biological Products Co., Ltd.
  • Harbin Pacific Bio-pharmaceutical Co., Ltd.
  • Hebei Daan Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Hunan Nanyue Pharmaceutical Co., Ltd.
  • Jiangxi Boya Bio-pharmaceutical Co., Ltd.
  • Shandong Taibang Products Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shanxi Kangbao Biological Product Co., Ltd.
  • Shenzhen Weiguang Biological Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Subordinate Institutions of Biological Products of China National Biotec Group
  • Walvax Biotechnology Co., Ltd.
  • Wuhan Rui De Biological Products Co., Ltd.
  • Zhenxing Biopharmaceutical & Chemical Inc.

For more information about this report visit https://www.researchandmarkets.com/research/rp4r8j/research_report

View source version on businesswire.com: http://www.businesswire.com/news/home/20171117005279/en/

Business Wire
www.businesswire.com

Last updated on: 17/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.